Quantcast

Reportlinker Adds Synthetic Biology: Emerging Global Markets Report

September 3, 2009

NEW YORK, Sept. 3 /PRNewswire-USNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Synthetic Biology: Emerging Global Markets

http://www.reportlinker.com/p0128136/Synthetic-Biology-Emerging-Global-Markets.html

This Report:

The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%.

The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%.

The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013.

Chapter-1: SUMMARY

SUMMARY 5

SUMMARY TABLE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, 2006-2013 ($ MILLIONS) 6

SUMMARY (CONTINUED) 7

Chapter-2: OVERVIEW

SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS REPORT 8

TABLE 1 SCOPE OF THIS REPORT 8

WHAT IS SYNTHETIC BIOLOGY? 8

WHAT IS SYNTHETIC BIOLOGY (CONTINUED) 9

DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY 10

FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH 10

TABLE 2 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 10

TABLE 2 (CONTINUED) 11

GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY PRODUCTS 12

TABLE 3 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS) 13

TABLE 4 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS) 14

LIFE CYCLE STATUS OF SYNTHETIC BIOLOGY TECHNOLOGIES 14

TABLE 5 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE 15

THE SYNTHETIC BIOLOGY INDUSTRY 15

TABLE 6 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS 16

THE SYNTHETIC BIOLOGY INDUSTRY (CONTINUED) 17

Chapter-3: SYNTHETIC BIOLOGY TECHNOLOGIES

INTRODUCTION 18

DEFINITION OF SYNTHETIC BIOLOGY 18

TABLE 7 SYNTHETIC BIOLOGY DEFINITIONS 18

HISTORY OF SYNTHETIC BIOLOGY 18

TABLE 8 SYNTHETIC BIOLOGY HISTORY 19

PARADIGM SHIFT IN BIOLOGY 20

TABLE 9 PARADIGM SHIFT OF BIOLOGY 20

TABLE 10 GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARED 21

FIGURE 1 SCALE OF SYNTHETIC BIOLOGY 22

SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW 23

TABLE 11 SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY 23

ENABLING TECHNOLOGIES 24

TABLE 12 IMPORTANCE OF ENABLING TECHNOLOGIES 24

COSTS OF DNA SYNTHESIS AND SEQUENCING 25

FIGURE 2 DNA SYNTHESIS AND SEQUENCING COSTS, 1990-2008 ($) 25

FIGURE 3 HUMAN GENOME SEQUENCING COSTS, 1990-2015 ($) 26

DNA SYNTHESIS TECHNOLOGIES 27

FIGURE 4 SIMPLIFIED SCHEMATIC OF GENE SYNTHESIS TECHNOLOGY 27

DNA Synthesis . . . (Continued) 28

TABLE 13 COMPARISON OF GENE SYNTHESIS TECHNOLOGIES 29

PCR-Based Approaches 29

Solid-Phase Approaches 30

MICROFLUIDICS TECHNOLOGIES 31

TABLE 14 IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY 31

DNA Microarrays–Oligos Synthesis 31

TABLE 15 MICROARRAY TYPES 32

TABLE 16 DNA MICROARRAY PLATFORM FEATURES 32

TABLE 17 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33

TABLE 17 (CONTINUED) 34

DNA Microarrays–. . .(Continued) 35

FIGURE 5 MICROARRAYS IN GENE SYNTHESIS 36

DNA SEQUENCING TECHNOLOGIES 36

DNA Sequencing TECHNOLOGIES (continued) 37

FIGURE 6 SEQUENCING THROUGHPUT TREND, 1977-2008 38

FIGURE 7 DNA SEQUENCING TECHNOLOGIES 39

BIOINFORMATICS TECHNOLOGIES 40

TABLE 18 SYNTHETIC BIOLOGY BIOINFORMATICS TECHNOLOGIES 41

BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS TECHNOLOGIES 41

TABLE 19 NUCLEIC ACIDS, GENES, AND GENOMES 41

SYNTHETIC GENES 42

TABLE 20 SYNTHETIC GENES AS MOLECULAR BIOLOGY TOOL 42

Synthetic Genes (Continued) 43

TABLE 21 SYNTHETIC GENES VERSUS PCR CLONING 44

BIOBRICKS/IGEM PARTS 45

TABLE 22 BIOBRICKS/IGEM PARTS 46

FIGURE 8 ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC BIOLOGY SYSTEMS 47

MINIMAL GENOMES AND CHASSIS ORGANISMS 48

TABLE 23 ATTRIBUTES OF A MINIMAL GENOME 48

Minimal Genomes and . . . (Continued) 49

CASE STUDY: MINIMAL E.COLI GENOME 50

Role of Directed Evolution in Designing Biologic Parts 50

ENABLED TECHNOLOGIES 51

OVERVIEW 51

TABLE 24 ENABLED TECHNOLOGIES: EXISTING AND NEAR-TERM APPLICATIONS 51

Pathway Engineering 52

FIGURE 9 HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS 52

TABLE 25 METABOLIC ENGINEERING FOR ARTEMISINIC ACID 53

Synthetic Microbial Consortia 54

TABLE 26 APPLICATIONS FOR SYNTHETIC MICROBIAL CONSORTIA 55

BIOFUELS TECHNOLOGIES 56

Biofuels Feedstocks 56

TABLE 27 ENERGY BALANCE OF SELECTED FIRST-GENERATION BIOFUEL FEEDSTOCKS 57

Advanced-Generation Biofuels 57

TABLE 28 FIRST- AND ADVANCED-GENERATION BIOFUELS COMPARED 58

Cellulosic Biomass 59

FIGURE 10 APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS (%) 59

TABLE 29 SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS INTO ETHANOL 60

Biofuels Types 61

TABLE 30 EFFICIENCY OF VARIOUS FUELS 61

Cellulosic Ethanol 62

FIGURE 11 CELLULOSIC ETHANOL PRODUCTION SCHEMATIC 62

TABLE 31 CORN ETHANOL COST TARGETS, 2009 ($/GAL. OF ETHANOL) 63

FIGURE 12 ESTIMATED 25 MGY CELLULOSIC ETHANOL PLANT COSTS (%) 64

Biodiesel 65

TABLE 32 IODINE NUMBER OF VARIOUS OILS 66

Other Biofuels 66

Role of Genetic Engineering and Synthetic Biology in Biofuels 66

TABLE 33 CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS 67

Chapter-4: SYNTHETIC BIOLOGY APPLICATIONS

INTRODUCTION 68

ENABLING TECHNOLOGIES 68

TABLE 34 SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES 68

BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS APPLICATIONS 69

TABLE 35 BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM APPLICATIONS 69

SYNTHETIC GENE APPLICATIONS 70

TABLE 36 SYNTHETIC GENES NEAR-TERM APPLICATIONS 70

Synthetic Gene Applications (Continued) 71

Synthetic Gene Applications (Continued) 72

BIOBRICKS/IGEM PARTS APPLICATIONS 73

INTEGRATED SYSTEMS APPLICATIONS 73

Synthetic Cells and Tissues 74

ENABLED PRODUCTS APPLICATIONS 75

TABLE 37 ENABLED PRODUCTS NEAR-TERM APPLICATIONS 75

APPLICATIONS BY END-USER INDUSTRY 76

RESEARCH AND DEVELOPMENT APPLICATIONS 76

TABLE 38 RESEARCH & DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 76

PHARMACEUTICALS APPLICATIONS 77

TABLE 39 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 77

Pharmaceuticals Applications (Continued) 78

TABLE 40 PIPELINE OF SYNTHETIC BIOLOGY-ENABLED DRUGS 79

ENERGY APPLICATIONS 80

TABLE 41 ETHANOL AND BIODIESEL FEEDSTOCKS AND PRODUCTION PROCESSES 80

TABLE 42 ETHANOL AND BIODIESEL COMMON BLENDS 81

TABLE 43 FIRST-GENERATION FUEL ETHANOL GLOBAL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 82

TABLE 44 FIRST-GENERATION BIODIESEL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 83

United States 83

FIGURE 13 RENEWABLE FUELS STANDARDS, UNITED STATES, 2008-2013 (BILLION GALS./ YR) 84

TABLE 45 DOE FUNDING FOR CELLULOSIC BIOFUELS, 2007-2011 ($ MILLIONS) 85

Canada 86

Brazil 87

CHEMICAL INDUSTRY APPLICATIONS 87

Chemical Industry Applications (Continued) 88

Chapter-5: SYNTHETIC BIOLOGY INDUSTRY

INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN 89

FIGURE 14 INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY LEVERAGE POINTS 90

INDUSTRY STRUCTURAL FORCES 91

TABLE 46 SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES 91

INDUSTRY STRUCTURAL FORCES (CONTINUED) 92

PRODUCTS AND TECHNOLOGY LIFE CYCLE 93

TABLE 47 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE 93

INDUSTRY COMPETITOR POSITIONING 94

TABLE 48 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS 95

GENE SYNTHESIS INDUSTRY 96

GENE SYNTHESIS WORKFLOW 96

TABLE 49 GENE SYNTHESIS WORKFLOW 96

Gene Synthesis Workflow (Continued) 97

GENE SYNTHESIS COMPETITOR STRATEGIES 98

FIGURE 15 SYNTHETIC GENE COMPANY ESTIMATED MARKET SHARES, 2008 (%) 99

Gene Synthesis . . . (Continued) 100

TABLE 50 SYNTHETIC GENE KEY COMPETITOR STRATEGIES 101

Gene Synthesis . . . (Continued) 102

Gene Synthesis Value Chain 103

Synthetic Gene Market Segments 104

Automated, Standardized Market Segment 104

Value-Added Market Segments 104

TABLE 51 GENE SYNTHESIS MARKET FACTORS OF DIFFERENTIATION 105

BIOFUELS INDUSTRY 106

COMPETITIVE DIFFERENTIATION 106

FEEDSTOCKS 107

TABLE 52 BIOFUELS: FEEDSTOCKS, PRODUCTION, AND PRODUCTS 107

FIGURE 16 BIOFUELS FEEDSTOCKS: RELATIVE COSTS AND VOLUMES 108

Sugars/Starches 108

Vegetable Oils 109

Biomass 109

Algae 109

TABLE 53 BIODIESEL YIELD OF SELECTED CROPS (GALS./ACRE/YR.) 109

CO2 110

CELLULOSIC ETHANOL INDUSTRY 111

TABLE 54 CELLULOSIC ETHANOL PLANTS (MGY) 111

Cellulosic Ethanol Industry (Continued) 112

BIOFUELS COMPETITOR STRATEGIES 113

TABLE 55 SYNTHETIC BIOLOGY-BASED BIOFUELS COMPANY STRATEGIES 114

TABLE 55 (CONTINUED) 115

Agrivida 115

Amyris 116

BP 116

DuPont 116

Gevo 116

LS9 117

Mascoma 117

OpX Biotechnologies 117

Sequesco 118

Solazyme 118

Synthetic Genomics 118

Verdezyne 118

Verenium 119

ROLE OF BIOFUELS FOUNDERS AND INVESTORS 119

TABLE 56 ROLE OF INVESTORS AND FOUNDERS IN BIOFUELS COMPANIES 119

ENZYMES INDUSTRY 120

TABLE 57 ENZYME COMPANY KEY ALLIANCES 121

PHARMACEUTICALS INDUSTRY 122

TABLE 58 PHARMACEUTICALS COMPANY STRATEGIES 122

INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES 123

TABLE 59 INDUSTRY ACQUISITIONS, 2006-2008 123

TABLE 60 SYNTHETIC BIOLOGY STRATEGIC ALLIANCES, 2006-2009 124

TABLE 60 (CONTINUED) 125

TABLE 60 (CONTINUED) 126

BIODEFENSE ISSUES 127

TABLE 61 FUTURE SYNTHETIC BIOLOGY SECURITY REGULATIONS 127

SUPPORTING INDUSTRY ORGANIZATIONS 128

TABLE 62 SYNTHETIC BIOLOGY ENABLING ORGANIZATIONS 128

TABLE 62 (CONTINUED) 129

SUPPORTING INDUSTRY . . . (CONTINUED) 130

FIGURE 17 GROWTH IN IGEM (NUMBER) 131

Chapter-6: SYNTHETIC BIOLOGY MARKETS

GROWTH DRIVING FORCES 132

TABLE 63 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 133

FIGURE 18 NIH BUDGET OUTLAYS, 2000-2009 ($ BILLIONS) 134

FIGURE 19 SYNTHETIC BIOLOGY RESEARCH PUBLICATIONS, 2000-2008 (NUMBER) 135

MARKET FORECASTS 136

FIGURE 20 MARKET FORECAST SCENARIO TABLE 136

SYNTHETIC BIOLOGY MARKETS BY INDUSTRY 137

Summary 137

TABLE 64 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS) 137

R&D Market 138

TABLE 65 GLOBAL VALUE OF R&D MARKET BY APPLICATION, THROUGH 2013 ($ MILLIONS) 138

Biotechnology and Pharmaceuticals Market 139

TABLE 66 GLOBAL VALUE OF BIOTECHNOLOGY AND PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 140

Chemicals Market 141

TABLE 67 GLOBAL VALUE OF CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 141

Energy Market 142

TABLE 68 GLOBAL VALUE OF ENERGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 142

FIGURE 21 S-CURVE FOR SECOND-GENERATION BIOFUELS 143

TABLE 69 WORLD BIODIESEL PRODUCTION AND CAPACITY TRENDS, 2002-2008 (MILLIONS TONS/YR) 144

TABLE 70 GLOBAL BIOFUELS SUPPLY BY PRODUCT CLASS, THROUGH 2013 (KBOED) 145

FIGURE 22 GLOBAL BIOFUELS MARKET, 2013 (GALS./YR.) 145

FIGURE 22 (CONTINUED) 146

FIGURE 23 GLOBAL CELLULOSIC SECOND-GENERATION BIOFUELS MARKET, 2013 (GALS./YR) 146

FIGURE 23 (CONTINUED) 147

FIGURE 24 UNITED STATES BIOFUELS MARKET GOALS, 2022 (%) 147

SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE 148

Summary 148

TABLE 71 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 148

Summary (Continued) 149

Enabling Products Market 150

TABLE 72 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLING PRODUCTS MARKET, THROUGH 2013 ($ MILLIONS) 150

Biological Parts Market 151

TABLE 73 GLOBAL VALUE OF DNA SYNTHESIS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 151

TABLE 74 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 152

Standardized Market Segment 152

Value-Added Market Segments 152

TABLE 75 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY END USER INDUSTRY, THROUGH 2013 ($ MILLIONS) 153

TABLE 76 GLOBAL VALUE OF BIOLOGIC PARTS BY SUPPLIER TYPE, THROUGH 2013 ($ MILLIONS) 154

TABLE 77 HOMEBREW VERSUS COMMERCIAL COST COMPARISON FOR SYNTHESIZING A TYPICAL 714 BP GFP GENE ($) 155

Integrated Systems Market 156

TABLE 78 GLOBAL VALUE OF SYNTHETIC BIOLOGY INTEGRATED SYSTEMS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 156

Enabled Products Market 156

TABLE 79 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED PRODUCTS MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 157

TABLE 80 GLOBAL VALUE OF ENABLED R&D MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 158

TABLE 81 GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 159

TABLE 82 GLOBAL VALUE OF ENABLED CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 160

TABLE 82 (CONTINUED) 161

TABLE 83 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS) 162

SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION 163

Summary 163

TABLE 84 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION, THROUGH 2013 ($ MILLIONS) 164

Importance of Geography to Fuels Markets 165

Importance of Geography . . . (Continued) 166

Chapter-7: PATENT STATUS

INTRODUCTION 167

FOUNDATIONAL PATENTS 167

TABLE 85 SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS 168

SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS 169

SYNTHETIC BIOLOGY INDUSTRY (continued) 170

FIGURE 25 NUMBER OF PATENTS BY COMPANY 171

FIGURE 25 (CONTINUED) 172

TABLE 86 PATENT DESCRIPTION BY COMPANY 173

FIGURE 26 SYNTHETIC BIOLOGY PATENTS BY COMPANY AND SUBCLASS (NUMBER OF PATENTS) 174

FIGURE 26 (CONTINUED) 175

LITIGATION STATUS 176

TABLE 87 IP LITIGATION STATUS 176

IP STRATEGY OF SELECTED SYNTHETIC BIOLOGY COMPANIES 177

METABOLIX 177

DUPONT 178

GENEART 178

FEBIT 179

Chapter-8: COMPANY PROFILES

AGRIVIDA 180

AMYRIS BIOTECHNOLOGIES, INC. 180

TABLE 88 AMYRIS BIODIESEL ADVANTAGES 181

ATG BIOSYNTHETICS GMBH 182

BASF AG 183

BIO BASIC, INC. 184

BIOCAT GMBH 184

BIONEER CORP. 185

BIONEXUS, INC. 185

BIO S&T, INC. 186

BIOTICA TECHNOLOGY, LTD. 186

BIOTICA TECHNOLOGY, LTD. (CONTINUED) 187

TABLE 89 STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN 188

TABLE 90 BIOTICA PROJECTS PIPELINE 189

BLUE HERON BIOTECHNOLOGIES 190

BRISTOL-MYERS SQUIBB 190

BRISTOL-MYERS SQUIBB (CONTINUED) 191

BRITISH PETROLEUM 192

CELLICON BIOTECHNOLOGIES, INC. 193

CODEXIS, INC. 194

CODON DEVICES, INC. 195

DANISCO A/S 195

DNA 2.0 196

TABLE 91 DNA2.0 STRATEGIC ALLIANCES 197

DRATHS CORP. 198

DUPONT 199

DUPONT (CONTINUED) 200

DYADIC INTERNATIONAL, INC. 201

ENTELECHON GMBH 201

EPOCH BIOLABS, INC. 202

ERAGEN BIOSCIENCES, INC. 203

EUROFINS MEDIGENOMIX GMBH 203

EUROFINS MWG OPERON 204

FEBIT SYNBIO GMBH 204

GENEART AG 205

TABLE 92 GENEART MAJOR STRATEGIC ALLIANCES 206

GENEART AG (CONTINUED) 207

GENEMED SYNTHESIS, INC. 208

GENSCRIPT CORP. 208

GENEWORKS PTY, LTD. 208

GEVO, INC. 209

TABLE 93 GEVO ISOBUTANOL PRODUCTION FORECAST (GALS./YR.) 209

HELICOS BIOSCIENCES CORP. 210

HELICOS BIOSCIENCES CORP. (CONTINUED) 211

HELICOS BIOSCIENCES CORP. (CONTINUED) 212

INTEGRATED DNA TECHNOLOGIES 213

ILLUMINA, INC. 213

ILLUMINA, INC. (CONTINUED) 214

INSTITUTE FOR ONEWORLD HEALTH 215

IOGEN CORP. 216

JOULE BIOTECHNOLOGIES, INC. 216

KHOSLA VENTURES 216

TABLE 94 KHOSLA VENTURES BIOFUELS INVESTMENT PORTFOLIO 217

LC SCIENCES 217

LIFE TECHNOLOGIES 218

LIFE TECHNOLOGIES (CONTINUED) 219

LS9, INC. 220

MASCOMA 221

TABLE 95 MASCOMA INTELLECTUAL PROPERTY STATUS 222

MAXYGEN 223

MERCK & CO. 224

METABOLIX, INC. 225

TABLE 96 METABOLOMIX BUSINESS STRATEGY 225

METRIGEN, INC. 226

NOVOZYMES A/S 227

OMEGA BIO-TEK, INC. 227

OPX BIOTECHNOLOGIES, INC. 228

PACIFIC BIOSCIENCES 229

PFIZER 230

PROTOLIFE SRL 231

QTEROS 232

ROCHE LIFE SCIENCES 232

ROCHE LIFE SCIENCES (CONTINUED) 233

ROYAL DSM N.V. 234

SANGAMO BIOSCIENCES, INC. 234

SANGAMO BIOSCIENCES, INC. (CONTINUED) 235

SANOFI AVENTIS 236

SCARAB GENOMICS, LLC 237

SEQUESCO 238

SLONING BIOTECHNOLOGY, GMBH 238

SOLAZYME, INC. 239

TABLE 97 SOLAZYME STRATEGIC ALLIANCES 240

SYNTHETIC GENOMICS 240

SYNTHETIC GENOMICS (CONTINUED) 241

TABLE 98 SYNTHETIC GENOMICS STRATEGIC ALLIANCES 242

VERDEZYNE 242

TABLE 99 VERDEZYNE STRATEGIC COLLABORATIONS 243

VERENIUM CORP. 244

VERENIUM CORP. (CONTINUED) 245

To order this report:

Synthetic Biology: Emerging Global Markets

http://www.reportlinker.com/p0128136/Synthetic-Biology-Emerging-Global-Markets.html

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus